Growth HormoneModerate Evidence

CJC-1295 with DAC

Also known as: CJC-1295 DAC, Drug Affinity Complex CJC

Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.

Evidence

Moderate

FDA status

Not FDA-approved

Source

Synthetic GHRH analog with drug affinity complex

Overview

Extended-release GHRH analog with drug affinity complex providing week-long GH elevation.

Mechanism of Action

GHRH analog with DAC modification binding to albumin for extended half-life (6-8 days), provides sustained GH and IGF-1 elevation, mimics continuous GHRH stimulation rather than pulsatile.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Long-lasting GH elevation
  • Sustained IGF-1 increase
  • Muscle growth support
  • Improved recovery
  • Body composition benefits

Researched for

Research topics, not approved uses.

Growth hormone deficiencyAge-related GH declineMuscle wastingBody composition goalsRecovery

How Gabriel approaches peptides

Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. CJC-1295 with DAC isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.

Read the peptide therapy guide

Research & Evidence

Evidence Level
Moderate
Studies

Clinical trials, pharmacokinetic studies

Summary

Clinical evidence for sustained GH and IGF-1 elevation. Provides continuous rather than pulsatile GH release, which may be less physiologic than modified GRF (CJC-1295 no DAC).

Safety Information

Potential Side Effects

  • •Water retention
  • •Increased hunger
  • •Numbness/tingling
  • •Headache
  • •Fatigue

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Pregnancy
  • Breastfeeding

Interactions

  • ⚠May affect glucose metabolism

Quick Facts

CategoryGrowth Hormone
SourceSynthetic GHRH analog with drug affinity complex
StatusNot FDA-approved